The global depression drugs market was valued at around US$ 15.3 Billion at the end of 2021. The market is projected to register a 3.7% CAGR and top a valuation of US$ 22.0 Billion by 2032.
The Rising prevalence of social anxiety and depression is expected to uplift the depression drugs market over the forecast period.
Depression is a mental disorder defined by a lack of pleasant feelings, a chronically depressed mood, and a wide range of cognitive, physical, behavioral, and emotional symptoms. It is diagnosed by determining the symptoms and reviewing the patient's medical history. The condition is then treated with antidepressants, which stabilize neurotransmitters like serotonin that function in the brain and regulate the patient's mood and emotions. These medications can help to lessen the symptoms of dysthymia, seasonal affective disorder, and anxiety.
| Attributes | Details |
| Depression Drugs Market Value in 2021 | US$ 15.3 Billion |
| Depression Drugs Market Value in 2032 | US$ 22.0 Billion |
| Depression Drugs Market CAGR (2022 to 2032) | 3.7% |
Depression is a prevalent mental disorder. According to estimates, 5% of the population worldwide experience depression. Depression is a major contributor to the overall global burden of disease, a primary cause of disability around the world, and it has an impact on the quality of life for those who are suffering from this condition. It is speculated that depression is more prevalent in women as compared to males. Over the forecast period, the market for depression drugs is anticipated to be driven by increased rates of social anxiety disorder, depression, and related illnesses.
The adoption rate is also rising as a result of the aging population, which is more vulnerable to certain medical problems. In the upcoming years, the depr4ession drugs market growth is predicted to be fueled by the development of novel therapies for the treatment of depression and the introduction of new antidepressants with negligible side effects and long-term outcomes.
The prevalence of mental health issues is rising, which is causing the market for treating depression to expand. These variables include demographic changes, environmental changes, mental stress, and more.
The depression drugs market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America is the leading region in the global depression drugs market owing to the increasing number of people suffering from depression and rising campaigns about mental health led by profitable and non-profitable organizations.
The European depression drugs market is also expected to display lucrative growth in the projected years due to a more aware and concerned populace regarding anxiety and depressive disorders.
The East Asian region is predicted to show lucrative growth owing to the growing knowledge amongst the general population about mental disorders and mental well-being.
Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals.
| Report Attributes | Details |
| Growth Rate | CAGR of 3.7% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Billion, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global depression drugs market is anticipated to register a CAGR of 3.7% during the forecast period.
The global depression drugs market is projected to be about US$ 22.0 Billion by the end of the year 2032.
Explore Similar Insights
Depression Drugs Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
